Table 1. Clinical findings and viremia for NHPs challenged with BEBOV.
| Animal | Group | Vaccinea | Signs Observed Between Day 0 and 28 after BEBOV challengeb | Serum Viremiad | Final Outcome |
| 6936CQ | 1 | PBS | Fever (6, 10), Anorexia (7–11), Depression (7–11), Rectorrhagia (11), Lymphopenia (6, 10), Thrombocytopenia (10, 11), ALP→→ (10), ALP→→→ (14), AST→→ (10, 11), BUN→ (10), BUN→→ (11), GGT→ (11) | 0/+(3), 5.6/++(6), 6.5/++(10) | Died on day 11 |
| 98C020 | 1 | PBS | Anorexia (8–14), Depression (7–13), Lymphopenia (6), Thrombocytopenia (6, 10), ALP→ (10), AST→→ (10), AST→ (14), BUN→ (10), GGT→ (10) | 0/+(3), 4.9/++(6), 3.4/++(10), 0/+(14) | Survived |
| 6942CQ | 1 | PBS | Fever (10), Anorexia (7–10), Depression (7–10), Epistaxis (10), Lymphopenia (6), Thrombocytopenia (10), ALP→ (10), AST→→→ (10), BUN→ (10), GGT→ (10) | 0/+(3), 4.2/++(6), 6.5/++(10) | Died on day10 |
| 6941CQ | 2 | rVSV-BEBOV-GP | Øc | 0/− | Survived |
| 91448 | 2 | rVSV-BEBOV-GP | Ø | 0/− | Survived |
| 121557 | 2 | rVSV-BEBOV-GP | Ø | 0/− | Survived |
| 98C007 * | 3 | rVSV Blend | Fever (6), Moderate rash (9–10), Anorexia (7–10), Depression (7–10), Lymphopenia (6), Thrombocytopenia (6) | 3.4/++(6) | Died on day 10 |
| 98C017 | 3 | rVSV Blend | Fever (6), Anorexia (7–14), Depression (7–14), Epistaxis (14), Lymphopenia (10), Thrombocytopenia (6, 10, 14), ALP→→ (6), ALP→→→(10, 14), BUN→ (10), BUN→→→ (14), GGT→ (10, 14) | 6.6/+++(6), 5.1/++(10), 6.1/++(14) | Died on day 14 |
| 91670 | 3 | rVSV Blend | Fever (6), Anorexia (7–10), Depression (7–10), Lymphopenia (6), | 1.7/++(6), 2.6/+(10) | Survived |
| 07411 | 4 | rVSV Prime-boost | Mild anorexia (9–11), ALP→ (10, 14), AST→→ (10), BUN→ (10) | 0/+(6) 0/+(10) | Survived |
| C07426 | 4 | rVSV Prime-boost | Ø | 0/− | Survived |
| 98C027 | 4 | rVSV Prime-boost | Mild fever (6), Mild anorexia (9–10), ALP→ (10) | 0/+(6) | Survived |
*98C007 expired before sampling at day 10 could be achieved.
a rVSV blend; rVSV-SEBOV-GP plus rVSV-ZEBOV-GP, rVSV Prime-boost; rVSV-SEBOV-GP first then rVSV-ZEBOV-GP 14 days after.
b Days after BEBOV challenge are in parentheses. Fever is defined as a temperature more than 2.5°F over baseline or at least 1.5°F over baseline and ≥103.5°F. Moderate rash refers to petechiae coverage of more than 20% of the skin. Lymphopenia and thrombocytopenia are defined by a ≥35% drop in numbers of lymphocytes and platelets, respectively. (ALP) alkaline phosphatase, (AST) aspartate aminotransferase, (BUN) blood urea nitrogen, (GGT) gamma glutamyltransferase: 2- to 3-fold increase,→; 4- to 5-fold increase, →→; >5 fold increase, →→→.
c No symptoms observed.
d Days after BEBOV challenge are in parentheses. Viral load for each day is depicted as: log10 PFU/ml/qRT-PCR positive (+) or negative (−). +, ≤5 log10; ++, ≥6 log10; +++, ≥7 log10.